Description
Rôles et compétences
Rôles et compétences
- Effectiveness of nurse-led mHealth interventions on symptom outcomes in adult patients with cancer: a systematic review and meta-analysison 3 novembre 2025
BMC Nurs. 2025 Oct 31;24(1):1356. doi: 10.1186/s12912-025-03981-2.NO ABSTRACTPMID:41174780 | DOI:10.1186/s12912-025-03981-2
Formation et apprentissage
- Qualitative Study of Health Care Professional Perspectives on Recruiting Minority Patients in Cancer Trialson 1 avril 2025
Health Equity. 2025 Jan 20;9(1):53-59. doi: 10.1089/heq.2024.0184. eCollection 2025.ABSTRACTBACKGROUND: Underrepresented minority (URM) patients enroll in cancer clinical trials at low rates. We […]
Spécialités cliniques
Oncologie médicale
- Novel drug-free cascaded nanoparticles induce tumor-specific ROS storms via multimodal synergistic anticancer therapyon 1 octobre 2025
J Nanobiotechnology. 2025 Sep 29;23(1):620. doi: 10.1186/s12951-025-03705-3.ABSTRACTReactive oxygen species (ROS), generated by sonosensitizers, play a pivotal role in tumor cell apoptosis during […]
Chirurgie oncologique
- Enhanced recovery after surgery in gastric cancer surgery: Systematic review and meta-analysis of perioperative indwelling drainage tube useon 3 novembre 2025
World J Gastrointest Surg. 2025 Oct 27;17(10):108930. doi: 10.4240/wjgs.v17.i10.108930.ABSTRACTBACKGROUND: The clinical necessity of routine abdominal drainage following radical gastrectomy remains […]
Radio-oncologie
- Camrelizumab Plus Famitinib versus Camrelizumab Alone and Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical Cancer: A Randomized, Phase II Studyon 15 juillet 2025
J Clin Oncol. 2025 Jun 25:JCO2402495. doi: 10.1200/JCO-24-02495. Online ahead of print.ABSTRACTPURPOSE: To compare camrelizumab (an anti-PD-1 monoclonal antibody) plus famitinib (a multitarget […]
Traitements et interventions
Traitements non-pharmacologiques
- Effects of Non-Pharmacological Interventions on Psychological Distress in Patients With Malignant Tumors: A Systematic Review and Network Meta-Analysison 3 novembre 2025
Worldviews Evid Based Nurs. 2025 Oct;22(5):e70076. doi: 10.1111/wvn.70076.ABSTRACTBACKGROUND: The incidence of psychological distress in patients with malignant tumors is high, which seriously […]
Approches complémentaires
- Effect of warm acupuncture and acupoint massage on postoperative gastrointestinal function in gastric cancer surgery patients: A meta-analysison 3 novembre 2025
World J Gastrointest Surg. 2025 Sep 27;17(9):106654. doi: 10.4240/wjgs.v17.i9.106654.ABSTRACTBACKGROUND: This study seeks to systematically assess the effects of warm acupuncture combined with […]
Réadaptation, physiothérapie et ergothérapie
- Impact of a self management mobile application on quality of life and limb circumference in women with breast cancer related lymphedemaon 2 octobre 2025
Sci Rep. 2025 Aug 18;15(1):30172. doi: 10.1038/s41598-025-15725-y.ABSTRACTBreast cancer-related lymphedema (BCRL) adversely affects the daily performance and quality of life (QoL) in affected […]
Éducation aux patients et littératie en santé
- Does cancer literacy predict cancer screening intention or uptake? A systematic reviewon 1 octobre 2025
Patient Educ Couns. 2025 Sep 8;141:109346. doi: 10.1016/j.pec.2025.109346. Online ahead of print.ABSTRACTOBJECTIVE: To examine the association between cancer literacy (CL) and cancer screening […]
Organisation des soins
Organisation et unités de soins
- What are the Key Components of an Advanced Nurse Practitioner (ANP) Led High-Risk Family History Breast Clinic? A Scoping Reviewon 3 novembre 2025
Semin Oncol Nurs. 2025 Sep 25:152018. doi: 10.1016/j.soncn.2025.152018. Online ahead of print.ABSTRACTOBJECTIVES: To identify what is known in the existing literature about the key components of an […]
Trajectoires de soins
- Brief Post-Surgical Stress Management Intervention Effects on Positive Psychological Well-Being and Self-Efficacy in Women Being Treated With Adjuvant Endocrine Therapy for Hormone-Receptor Positive Breast Canceron 11 septembre 2025
Psychooncology. 2025 Aug;34(8):e70267. doi: 10.1002/pon.70267.ABSTRACTBACKGROUND: Women prescribed adjuvant endocrine therapy (AET) for nonmetastatic breast cancer may experience a decline in […]
Performance et indicateurs
- The Cost-Effectiveness of Nursing Interventions in Cancer Care: Systematic Review.on 11 septembre 2025
Seminars in Oncology Nursing; 08/01/2025This study aimed to comprehensively examine the studies evaluating the cost impact of nursing intervention in cancer care. PubMed, Scopus, Web of Science, […]
Amélioration de la qualité et meilleures pratiques
- Advance Care Planning in Oncology Nursing: An Interpretive Description Study.on 1 octobre 2025
Journal of Advanced Nursing (John Wiley & Sons, Inc.); 10/01/2025Aim: To explore oncology nursing advance care planning practices and understand how to better support nurses in conducting advance […]
Innovation
- Mitigating Ethical Issues for Large Language Models in Oncology: A Systematic Reviewon 1 octobre 2025
JCO Clin Cancer Inform. 2025 Sep;9:e2500076. doi: 10.1200/CCI-25-00076. Epub 2025 Sep 24.ABSTRACTPURPOSE: Large language models (LLMs) have demonstrated remarkable versatility in oncology […]
Expériences des patients
Expériences des patients
- Living with pain-a systematic review on patients' subjective experienceson 3 novembre 2025
Syst Rev. 2025 Oct 6;14(1):188. doi: 10.1186/s13643-025-02953-6.ABSTRACTBACKGROUND: Understanding the subjective experiences of patients living with chronic, acute, and cancer pain can significantly […]
Participation des patients
- Intervention studies on shared decision-making with adult patients for treatment among cancer: A systematic review and meta-analysison 2 octobre 2025
Medicine (Baltimore). 2025 Sep 12;104(37):e44025. doi: 10.1097/MD.0000000000044025.ABSTRACTBACKGROUND: Patients have the right to participate in the decision-making on their treatments. A shared […]
Résultats rapportés par les patients
- Measuring what matters to patients: Systematic literature review of patient-reported outcomes assessment and reporting in locally advanced or metastatic urothelial cancer real-world and clinical studieson 3 novembre 2025
Urol Oncol. 2025 Oct 27:S1078-1439(25)00384-9. doi: 10.1016/j.urolonc.2025.09.016. Online ahead of print.ABSTRACTINTRODUCTION: A systematic literature review (SLR) was conducted to evaluate […]
Survivance
- A systematic review and meta-analysis of randomized controlled trials on the effects of high-intensity interval training in breast cancer survivorson 3 novembre 2025
Clin Rehabil. 2025 Oct 3:2692155251383151. doi: 10.1177/02692155251383151. Online ahead of print.ABSTRACTObjectiveExercise is a well-recognized, safe, and effective strategy for breast cancer […]
Publications d'associations professionnelles
Canadian Association of Nurses in Oncology (CANO/ACIO)
- Therapeutic breakthroughs in oncology: Enhancing treatment and managementon 11 septembre 2025
Can Oncol Nurs J. 2025 Jul 1;35(4):590-605. doi: 10.5737/23688076354590. eCollection 2025.ABSTRACTRecent advancements in oncology have significantly transformed cancer treatment and care management, offering new hope to patients worldwide. This literature review examines key therapeutic breakthroughs, including targeted therapies, immunotherapies, personalized medicine, and innovative drug delivery systems. These cutting-edge interventions have enhanced patient outcomes, improving survival rates and quality of life, but they have also introduced complexities in managing emerging side effects, care coordination, and resource allocation. This review discusses the implications of these therapies on patient care, the ethical considerations they entail, the management of side effects, and the pivotal role of oncology nurses in administering and managing these treatments. By exploring the current landscape and future directions of oncology therapies, including areas such as cancer vaccines and precision medicine, this article provides a comprehensive understanding of how these innovations are shaping the future of cancer care.PMID:40873601 | PMC:PMC12379890 | DOI:10.5737/23688076354590
Oncology Nursing Society (ONS)
- DPYD Gene and DPD Enzyme Huddle Cardon 3 novembre 2025
DPYD Gene and DPD Enzyme Huddle Card Kristina M. Gantner October 27, 2025 Teaser text Review this huddle card in a group or individually to learn more about the DPYD gene and DPD enzyme.
American Society of Clinical Oncology (ASCO)
- Large Language Models in Population Oncology: A Contemporary Review on the Use of Large Language Models to Support Data Collection, Aggregation, and Analysis in Cancer Care and Researchon 3 novembre 2025
JCO Clin Cancer Inform. 2025 Oct;9:e2500112. doi: 10.1200/CCI-25-00112. Epub 2025 Oct 24.ABSTRACTOver the past 5 years, large language models (LLMs) have emerged and continued to improve in their generative abilities and are now capable of generating human-understandable text and performing complex data analyses. As these models continue to improve in their capabilities, they are increasingly used to support population oncology, including clinical information extraction, cancer care education, and clinical decision support. This narrative review provides a high-level description of the use of LLMs in cancer with an overview of the current literature, along with research gaps. Despite increasing interest in using LLMs for cancer care, prevention, and research, applied methods in cancer still lag advancements published in the computer science literature. Therefore, we recommend that cancer-focused LLM research and applications better incorporate technical advancements and techniques found in the computer science literature. Additionally, standardized evaluation metrics and approaches need to be better studied and adopted in oncology, along with data governance and computational infrastructure to support state-of-the-art model integration and the use of real-world data. Finally, we describe the need for researchers to incorporate principles and frameworks from implementation and dissemination science to promote LLM-based tool adaptation, effectiveness, fit, and sustainability.PMID:41135040 | DOI:10.1200/CCI-25-00112
National Comprehensive Cancer Network (NCCN)
- Smoking Cessation and Mortality Risk in Cancer Survivorship: Real-World Data From a National Cancer Institute-Designated Cancer Centeron 3 novembre 2025
J Natl Compr Canc Netw. 2025 Oct;23(10):e257059. doi: 10.6004/jnccn.2025.7059.ABSTRACTBACKGROUND: Although evidence-based tobacco cessation treatments are recommended for all patients with cancer who smoke, they are often underutilized in routine oncology care due to time and resource constraints and limited understanding of the impact of smoking cessation on long-term outcomes in patients with advanced-stage cancer. This study aimed to evaluate the association between smoking cessation and overall survival (OS) in cancer survivors who smoke, across all disease stages.METHODS: We conducted an observational cohort study of 13,282 patients diagnosed with cancer who were evaluated in our outpatient oncology clinics between June and December 2018. Patients who smoked were prospectively followed to evaluate smoking cessation rates over the following 6 months. We assessed the impact of index-visit smoking status and smoking cessation within 6 months on 2-year OS using multivariable Cox proportional hazards models and the Kaplan-Meier method.RESULTS: Compared with patients who never smoked (n=6,568; 49.5%), those who reported currently smoking (n=1,725; 13.0%) (adjusted hazard ratio for death [aHR], 1.35; CI, 1.20-1.53) or having previously smoked (n=4,989; 37.6%) (aHR, 1.13; CI, 1.03-1.25) at their index visit had increased risk of all-cause mortality. Only 22.1% (n=381) of patients who reported currently smoking at their index visit quit smoking within 6 months. In multivariable analyses, patients who continued to smoke had a higher risk of all-cause mortality (aHR, 1.97; CI, 1.53-2.55) compared with those who had quit smoking. Subgroup analyses by cancer stage revealed an association between continued smoking and all-cause mortality in patients with advanced-stage (III or IV) cancer (aHR, 2.11; 95% CI, 1.60-2.79).CONCLUSIONS: Postdiagnosis smoking cessation is associated with improved OS in cancer survivors, including those with advanced-stage cancer. Smoking cessation support should be provided to all cancer survivors who smoke, irrespective of cancer type or stage. Promoting smoking cessation in oncology care settings via systematic implementation efforts may aid in reducing smoking and mortality rates.PMID:41067270 | DOI:10.6004/jnccn.2025.7059
European Society for Medical Oncology (ESMO)
- EMA Recommends Extension of Indications for Sugemalimab on 3 novembre 2025
New indication concerns monotherapy for the treatment of unresectable stage III NSCLC with no genomic alterations
Pour obtenir les documents
L’accès au texte intégral des documents est restreint au personnel et aux médecins du CHUM en fonction des abonnements de la bibliothèque. Certains documents sont en accès libre sur le web.
Si vous êtes branchés sur le réseau CHUM :
Cliquer sur les liens fournis pour chaque référence pour vérifier la disponibilité du texte intégral.
Pour les articles provenant de PubMed, cliquer préalablement sur le lien suivant pour afficher la disponibilité du document.
Si vous êtes dans un autre établissement et que vous n’arrivez pas à accéder au texte intégral d’un article à partir du lien donné, vérifier auprès de la bibliothèque de votre institution en donnant la référence complète du document.
|
Avis de non-responsabilité
Le contenu des veilles informationnelles ou stratégiques (ci-après appelée « Veilles ») est mis à votre disposition à titre informatif pour un usage personnel exclusif. Tout usage commercial du contenu des Veilles est strictement interdit. Tous les éléments, articles, rapports ou toute autre source d’information figurant dans les Veilles, vous sont fournis « tels quels », sans garantie d’aucune sorte. Eu égard aux propos tenus dans les articles et les rapports sélectionnés pour les Veilles, le CHUM n’offre aucune garantie notamment d’exhaustivité, de fiabilité, d’actualité et d’exactitude.Le CHUM ne pourra en aucun cas être tenu responsable envers quiconque de tout dommage quel qu’il soit, même ceux directs, encouru notamment des suites de toute réclamation, action ou poursuite découlant, même directement, de l’utilisation de ces Veilles.
Les Veilles contiennent des liens vers des sites Web créés et mis à jour par des tierces parties. Ces liens sont fournis pour la commodité des utilisateurs seulement. Le CHUM n’endosse et ne garantit, ni explicitement ni implicitement, l’exactitude ou l’intégralité ni du contenu de ces hyperliens ni des opinions qui y sont exprimées. Le CHUM n’assume aucune responsabilité à l’égard de ces sites Web externes.
Le CHUM prend tous les moyens raisonnables afin de respecter les droits de propriété intellectuelle afférents au contenu des Veilles et aux modalités du prêt entre bibliothèques, émises par l’Université de Montréal. Le contenu des Veilles, incluant la manière dont il est présenté, sont notamment protégés par la Loi sur le droit d’auteur (L.R.C. (1985), ch. C-42). Le CHUM ne donne aucune garantie et ne fait aucune déclaration à l’effet que le contenu de ces veilles n’enfreint aucun droit d’une autre personne ou entité. Le téléchargement, la reproduction en un seul exemplaire ou le tirage sur papier des Veilles ne sont autorisés qu’à des fins de sauvegarde et pour un usage privé et non commercial. Tout téléchargement, reproduction, édition, diffusion sur Internet, utilisation à des fins commerciales ou publiques, distribution, publication sur un autre site ou sur quelque autre forme ainsi que toute autre utilisation est strictement interdite, à moins d’être faite dans le respect des règles de propriété intellectuelle applicables. |


